PURPOSE: The contribution of axonal injury to brain damage after aneurysmal subarachnoid haemorrhage (aSAH) is unknown. Neurofilament light chain (NF-L), a component of the axonal cytoskeleton, has been shown to be elevated in the cerebrospinal fluid of patients with many types of axonal injury. We hypothesised that patients with aSAH would have elevated cerebrospinal fluid (CSF) NF-L levels and sought to explore the clinical correlates of CSF NF-L dynamics. METHODS: Serial ventricular CSF (vCSF) samples were collected from 35 patients with aSAH for up to 15 days. vCSF NF-L measurements were determined by enzyme-linked immunosorbent assay. NF-L levels were analysed in relation to acute clinical status, radiological findings and 6-month outcomes. RESULTS: vCSF NF-L concentrations were elevated in all patients with aSAH. Patients with early cerebral ischaemia (ECI), defined as a CT hypodense lesion visible within the first 3 days, had higher acute vCSF NF-L levels than patients without ECI. These elevated NF-L levels were similar in patients with ECI associated with intracranial haemorrhage and ECI associated with surgical/endovascular complications. vCSF NF-L levels did not differ as a function of acute clinical status, clinical vasospasm, delayed cerebral ischaemia or 6-month Glasgow Outcome Scale. CONCLUSIONS: Elevated vCSF NF-L levels may in part reflect increased injury to axons associated with ECI. However, our results suggest that axonal injury after aSAH as reflected by release of NF-L into the CSF may not play a major role in either secondary adverse events or long-term clinical outcomes.
PURPOSE: The contribution of axonal injury to brain damage after aneurysmal subarachnoid haemorrhage (aSAH) is unknown. Neurofilament light chain (NF-L), a component of the axonal cytoskeleton, has been shown to be elevated in the cerebrospinal fluid of patients with many types of axonal injury. We hypothesised that patients with aSAH would have elevated cerebrospinal fluid (CSF) NF-L levels and sought to explore the clinical correlates of CSFNF-L dynamics. METHODS: Serial ventricular CSF (vCSF) samples were collected from 35 patients with aSAH for up to 15 days. vCSF NF-L measurements were determined by enzyme-linked immunosorbent assay. NF-L levels were analysed in relation to acute clinical status, radiological findings and 6-month outcomes. RESULTS: vCSF NF-L concentrations were elevated in all patients with aSAH. Patients with early cerebral ischaemia (ECI), defined as a CT hypodense lesion visible within the first 3 days, had higher acute vCSF NF-L levels than patients without ECI. These elevated NF-L levels were similar in patients with ECI associated with intracranial haemorrhage and ECI associated with surgical/endovascular complications. vCSF NF-L levels did not differ as a function of acute clinical status, clinical vasospasm, delayed cerebral ischaemia or 6-month Glasgow Outcome Scale. CONCLUSIONS: Elevated vCSF NF-L levels may in part reflect increased injury to axons associated with ECI. However, our results suggest that axonal injury after aSAH as reflected by release of NF-L into the CSF may not play a major role in either secondary adverse events or long-term clinical outcomes.
Authors: K Nylén; L Z Csajbok; M Ost; A Rashid; J-E Karlsson; K Blennow; B Nellgård; L Rosengren Journal: Neurosci Lett Date: 2006-06-27 Impact factor: 3.046
Authors: Andrew M Naidech; Kurt T Kreiter; Nazli Janjua; Noeleen D Ostapkovich; Augusto Parra; Christopher Commichau; Brian-Fred M Fitzsimmons; E Sander Connolly; Stephan A Mayer Journal: Circulation Date: 2005-11-01 Impact factor: 29.690
Authors: D de Jong; R W M M Jansen; Y A L Pijnenburg; W J A van Geel; G F Borm; H P H Kremer; M M Verbeek Journal: J Neurol Neurosurg Psychiatry Date: 2007-02-21 Impact factor: 10.154
Authors: Elisa R Zanier; Giovanna Brandi; Giuseppe Peri; Luca Longhi; Tommaso Zoerle; Mauro Tettamanti; Cecilia Garlanda; Anna Sigurtà; Serenella Valaperta; Alberto Mantovani; Maria Grazia De Simoni; Nino Stocchetti Journal: Intensive Care Med Date: 2010-11-12 Impact factor: 17.440
Authors: Sandra Magnoni; Thomas J Esparza; Valeria Conte; Marco Carbonara; Giorgio Carrabba; David M Holtzman; Greg J Zipfel; Nino Stocchetti; David L Brody Journal: Brain Date: 2011-11-23 Impact factor: 13.501
Authors: Peter B Forgacs; Baxter B Allen; Xian Wu; Linda M Gerber; Srikanth Boddu; Malik Fakhar; Philip E Stieg; Nicholas D Schiff; Halinder S Mangat Journal: Neurocrit Care Date: 2021-10-20 Impact factor: 3.210
Authors: Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard Journal: Biomarkers Date: 2014-02-05 Impact factor: 2.658
Authors: Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Prashanthi Vemuri; Mary M Machulda; Jonathan Graff-Radford; David S Knopman; Clifford R Jack; Ronald C Petersen; Silke Kern Journal: Alzheimers Dement Date: 2019-10-23 Impact factor: 21.566
Authors: Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews Journal: Brain Date: 2020-07-01 Impact factor: 13.501